The Trade and Cooperation Agreement provides for zero tariff zero quota trade, with modern rules of origin for the automotive sector that reflect UK manufacturing and are designed to support the industry through its transition to electrification. The phased approach to rules of origin for batteries gives industry time to localise supply chains for electrified vehicles.<\/p>
<\/p>
The Government has prioritised securing investment in battery cell gigafactories, which is key for anchoring the mass manufacture of electric vehicles, safeguarding and creating high quality jobs across the UK, and driving emissions to net zero by 2050.<\/p>
<\/p>
As part of my Rt. Hon. Friend the Prime Minister\u2019s 10 Point Plan for a green industrial revolution, nearly £500m of funding for the Automotive Transformation Fund will be made available in the next four years to build an internationally competitive electric vehicle supply chain. This is a UK-wide programme, and we are welcoming applications for support from businesses and investors across the country.<\/p>
<\/p>
We continue to work closely with investors to progress plans for manufacturing the batteries that we will need for the next generation of electric vehicles here in the UK.<\/p>
<\/p>
The Government is also investing £318m, through the Industrial Strategy Challenge Fund in the Faraday Battery Challenge, to put the UK at the global forefront of the design, development, manufacturing, and recycling of electric batteries.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"} } , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"} , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"} , "dateOfAnswer" : {"_value" : "2021-03-09", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2021-03-09T10:28:10.947Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "201"} , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"} , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"} , "date" : {"_value" : "2021-03-01", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Electric Vehicles: UK Trade with EU"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, what recent assessment he has made of the need to support UK manufacturing capacity for vehicle batteries to avoid future tariffs on electric vehicles under the rules of the UK-EU free trade agreement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4716", "label" : {"_value" : "Biography information for Ruth Jones"} } , "tablingMemberConstituency" : {"_value" : "Newport West"} , "tablingMemberPrinted" : [{"_value" : "Ruth Jones"} ], "uin" : "160801"} , {"_about" : "http://data.parliament.uk/resources/1285176", "AnsweringBody" : [{"_value" : "Department for Business, Energy and Industrial Strategy"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1285176/answer", "answerText" : {"_value" : "
The Government is undertaking laboratory work as a priority to better understand the impact of the new Covid-19 variants on the vaccines currently in deployment, in particular the risk of vaccine resistance. We maintain close contact with vaccine developers to understand their efficacy studies of their vaccines on variants and the impact on current supply chain arrangements for their manufacture.<\/p>
<\/p>
We continue to take a portfolio-based approach that monitors the landscape of Covid-19 vaccine development and we remain confident that the three vaccines (Pfizer/BioNTech, Oxford University/AstraZeneca, and Moderna) that we have purchased, which have been authorised by the Medicines and Healthcare products Regulatory Agency, will continue to be effective against the virus.<\/p>
<\/p>
The Government has also established a new partnership with the vaccine manufacturer, CureVac, to rapidly develop new vaccines in response to new Covid-19 variants, should this be needed. The new agreement will utilise UK expertise on genomics and virus sequencing to allow new varieties of vaccines based on messenger RNA technology to be developed quickly against new strains of Covid-19 if they are needed. An initial order has been made for 50 million doses.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"} } , "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"} , "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"} , "dateOfAnswer" : {"_value" : "2021-02-17", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2021-02-17T15:59:17.693Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "201"} , "answeringDeptShortName" : {"_value" : "Business, Energy and Industrial Strategy"} , "answeringDeptSortName" : {"_value" : "Business, Energy and Industrial Strategy"} , "date" : {"_value" : "2021-02-09", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Business, Energy and Industrial Strategy, what recent assessment he has made of the adequacy of the resources available to vaccine manufacturers seeking to keep up with emerging variants of covid-19.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4716", "label" : {"_value" : "Biography information for Ruth Jones"} } , "tablingMemberConstituency" : {"_value" : "Newport West"} , "tablingMemberPrinted" : [{"_value" : "Ruth Jones"} ], "uin" : "151843"} , {"_about" : "http://data.parliament.uk/resources/1285239", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1285239/answer", "answerText" : {"_value" : "
Public Heath England\u2019s surveillance strategy will monitor how effective the vaccine is at protecting against a range of outcomes, including infection, symptomatic disease, hospitalisations, mortality and onward transmission. The surveillance strategy is available at the following link:<\/p>
https://www.gov.uk/government/publications/covid-19-vaccine-surveillance-strategy<\/a>.<\/p> The National Institute for Health Research (NIHR) and UK Research and Innovation (UKRI), are jointly funding the UK Coronavirus Immunology Consortium (UK-CIC) to address key questions around the immune system\u2019s response to COVID-19. The NIHR\u2019s Health Protection Research Unit in Respiratory Infections is also looking at the size and longevity of the immune response.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4113", "label" : {"_value" : "Biography information for Nadhim Zahawi"}
}
, "answeringMemberConstituency" : {"_value" : "Stratford-on-Avon"}
, "answeringMemberPrinted" : {"_value" : "Nadhim Zahawi"}
, "dateOfAnswer" : {"_value" : "2021-03-05", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2021-03-05T16:06:18.433Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2021-02-09", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Coronavirus: Vaccination"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what plans he has to implement a long term study of immune responses in people vaccinated against covid-19.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4716", "label" : {"_value" : "Biography information for Ruth Jones"}
}
, "tablingMemberConstituency" : {"_value" : "Newport West"}
, "tablingMemberPrinted" : [{"_value" : "Ruth Jones"}
], "uin" : "151844"}
, {"_about" : "http://data.parliament.uk/resources/1285240", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1285240/answer", "answerText" : {"_value" : " Public Health England has published early estimates of vaccine effectiveness which includes the United Kingdom variant of concern which is available at the following link:<\/p>